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Background: Some evidence suggests that the direct renin inhibitor
aliskiren may increase the risk of severe hyperkalemia, stroke, or
acute kidney injury (AKI) when prescribed with angiotensin-converting
enzyme inhibitors (ACEi’s) or angiotensin-receptor blockers (ARBs). The
extent to which concomitant treatment increases the risk of these
outcomes in routine clinical practice is unknown. We addressed this
issue with the use of administrative databases.
Methods:We established a cohort of Ontarians treated with an ACEi or
an ARB. Within this cohort, we conducted 3 case-control studies. Cases
were patients hospitalized with 1 of 3 outcomes (hyperkalemia, AKI, or
stroke). In each analysis, we identiﬁed up to 5 matched control
subjects for each case. Conditional logistic regression was used to
examine the association between hospitalization for each outcome
and the use of aliskiren in the preceding 60 days.Received for publication January 23, 2013. Accepted February 18, 2013.
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Introduction : Certaines donnees scientiﬁques suggèrent que l’inhibi-
teur direct de la renine, l’aliskirène, peut augmenter le risque d’hy-
perkaliemie grave, d’accident vasculaire cerebral (AVC) ou
d’insufﬁsance renale aiguë (IRA) lorsqu’il est prescrit en association
avec les inhibiteurs de l’enzyme de conversion de l’angiotensine (IECA)
ou les antagonistes des recepteurs de l’angiotensine (ARA). La mesure
dans laquelle ces traitements concomitants augmentent le risque de
ces resultats dans la pratique clinique courante demeure inconnue.
Nous abordons ce problème par l’utilisation de bases de donnees
administratives.
Methodes : Nous avons etabli une cohorte d’Ontariens traites par un
IECA ou un ARA. À partir de cette cohorte, nous avons mene 3 etudes
cas-temoins. Les cas etaient de patients hospitalises ayant 1 des 3
resultats cliniques (hyperkaliemie, IRA ou AVC). Dans chacune desDrugs that modulate the renin-angiotensin-aldosterone RAAS inhibitors are angiotensin-converting enzyme inhibitors
system (RAAS) are increasingly important in the care of
patients with cardiovascular disease, particularly those with
hypertension and heart failure. The most commonly used(ACEi’s), angiotensin-receptor blockers (ARBs), and spi-
ronolactone, all of which have established mortality beneﬁts in
appropriately selected patients.1-4
Approved by the US Food and Drug Administration in
2007, aliskiren is the ﬁrst commercially available direct renin
inhibitor. Aliskiren binds to the S3bp binding pocket of renin,
preventing the conversion of angiotensinogen to angiotensin I,
the rate-limiting step in the RAAS cascade.5 Because renin
inhibitors do not inﬂuence kinin metabolism, they are thought
to confer fewer adverse effects than ACEi’s do. Clinical trialsd by Elsevier Inc. All rights reserved.
Results: Among 903,346 patients aged 66 years and older treated
with an ACEi or ARB during the 28-month study period, we identiﬁed
4235 hospitalized with hyperkalemia, 18,231 hospitalized with AKI,
and 8283 hospitalized with stroke. After extensive multivariable
adjustment, aliskiren therapy was not associated with a signiﬁcant
increase in the risk of hospitalization for hyperkalemia, AKI, or stroke.
We found similar results in stratiﬁed analyses of patients with and
without a history of chronic kidney disease, diabetes, or heart failure.
Conclusions: Among community-dwelling patients aged 66 years and
older receiving therapy with an ACEi or an ARB, aliskiren use was not
associated with hospitalization for hyperkalemia, AKI, or stroke.
analyses, nous avons identiﬁe jusqu’à 5 temoins apparies à chacun
des cas. La regression logistique conditionnelle a ete utilisee pour
examiner le lien entre l’hospitalisation pour chacun des resultats
cliniques et l’utilisation de l’aliskirène dans les 60 jours precedents.
Resultats : Parmi les 903 346 patients âges de 66 ans et plus qui ont
ete traites par un IECA ou un ARA durant la periode d’etude de 28
mois, nous avons identiﬁe 4235 patients hospitalises ayant eu une
hyperkaliemie, 18 231 patients hospitalises ayant eu une IRA et 8283
patients hospitalises ayant eu un AVC. Après l’ajustement multivarie
complet, le traitement à l’aliskirène n’a pas ete associe à une
augmentation signiﬁcative du risque d’hospitalisation pour une
hyperkaliemie, une IRA ou un AVC. Nous avons observe des resultats
similaires dans les analyses stratiﬁees de patients ayant des
antecedents ou n’ayant pas d’antecedents de maladie renale chron-
ique, de diabète ou d’insufﬁsance cardiaque.
Conclusions : Parmi les patients vivant dans la communaute qui
etaient âges de 66 ans et plus et qui recevaient un traitement par un
IECA ou un ARA, l’utilisation de l’aliskirène n’a pas ete associee à
l’hospitalisation pour une hyperkaliemie, une IRA ou un AVC.
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Risks Associated With Aliskiren Usehave shown that aliskiren lowers blood pressure in combination
with an ACEi or an ARB,6-8 but its place in therapy is still
unclear.9 It is presently approved in Canada and the United
States as a third-line agent in resistant hypertension, and in
Europe as monotherapy or as part of combination therapy.
Hyperkalemia is a well-recognized and potentially life-
threatening adverse effect of drugs that interfere with the
RAAS, particularly when they are used in combination.10 It
remains unclear whether aliskiren is associated with a clini-
cally important increase in the risk of hyperkalemia in this
setting. One case report describes hyperkalemia in association
with aliskiren and coexisting acute kidney injury (AKI).11
Small randomized trials have yielded inconsistent ﬁndings
regarding the risk of hyperkalemia during aliskiren therapy,
but a meta-analysis by Harel et al. found a signiﬁcantly
increased risk of moderate but not severe hyperkalemia.12
Recently, a large multicentre randomized trial (Aliskiren
Trial in Type 2 Diabetes Using Cardiorenal Endpoints
[ALTITUDE]) was halted on the basis of futility and safety
after an interim analysis determined that patients receiving
aliskiren together with an ACEi or ARB were at increased risk
of hyperkalemia, AKI, and stroke.13 Consequently, several
class action lawsuits have been initiated regarding the drug’s
safety.14
Because clinical trials have yielded conﬂicting information
about adverse events regarding the use of aliskiren in combi-
nation with other blockers of the RAAS, and because patients
in clinical practice generally differ from those in clinical trials,
we sought to characterize the risk of hospitalization for severe
hyperkalemia, AKI, and stroke during aliskiren therapy in
a cohort of patients aged 66 years and older receiving an ACEi
or an ARB.Methods
Data sources
We conducted 3 population-based, nested case-control
studies involving Ontarians aged 66 years or older treated
with either an ACEi or an ARB between December 1, 2008,and March 31, 2011. We used the Ontario Public Drug
Program database to identify dispensed prescription medica-
tions. This database has an overall error rate of less than 1%.15
Hospitalization data and demographic information were ob-
tained from the Canadian Institute for Health Information
Discharge Abstract Database and the Registered Persons
Database, respectively. The Discharge Abstract Database
contains diagnosis codes regarding all hospital admissions,
discharges, and same-day surgical procedures. The Ontario
Health Insurance Plan database provided information
regarding claims for all physician services, and the presence of
diabetes was established using the Ontario Diabetes Data-
base.16 The data were held securely in a linked, deidentiﬁed
form and analyzed at the Institute for Clinical Evaluative
Sciences. This is regularly done to study postmarket drug
safety, including risk factors for hyperkalemia, AKI, and
stroke.10,17-20
Identiﬁcation of study subjects
For each patient treated with an ACEi or an ARB, we
identiﬁed a period of continuous therapy beginning with the
ﬁrst such prescription following the patient’s 66th birthday.
The observation period within each case-control study ended
with the ﬁrst occurrence of hospitalization with the primary
end-point, death, or discontinuation of treatment with an
ACEi or an ARB, whichever occurred ﬁrst. Continuous use of
ACEi’s and ARBs was deﬁned as the receipt of a reﬁll for the
drug within 1.5 times the number of days covered by the
previous prescription.21 Patients who discontinued treatment
were followed throughout the duration of their last prescrip-
tion to identify any events that might have precipitated
cessation of therapy. It should be noted that although drugs
were identiﬁed, doses were not.
Within this cohort we identiﬁed cases as those patients
hospitalized with a diagnosis of hyperkalemia (International
Classiﬁcation of Diseases, Tenth Revision [ICD-10] code
E87.5), AKI (ICD-10 codes N17 and R34), and stroke (ICD-
10 codes I63 and I64). We included only patients who had
these outcomes on hospital admission, and excluded those in
Table 1. Baseline characteristics for cases and matched controls
Variable
Hyperkalemia Acute kidney injury Stroke
Control
(N ¼ 21,106)
Case
(N ¼ 4235)
Control
(N ¼ 77,916)
Case
(N ¼ 18,231)
Control
(N ¼ 41,407)
Case
(N ¼ 8283)
Median age (years) 80 81 81 81 81 81
Age categories, n (%)
66-75 years 6313 (29.9) 1261 (29.8) 22,833 (29.3) 5152 (28.3) 11,752 (28.4) 2350 (28.4)
76-85 years 9511 (45.1) 1862 (44.0) 34,942 (44.9) 8237 (45.2) 18,715 (45.2) 3743 (45.2)
86þ years 5282 (25.0) 1112 (26.3) 20,141 (25.9) 4842 (26.6) 10,940 (26.4) 2190 (26.4)
Male, n (%) 10,274 (48.7) 2062 (48.7) 38,607 (49.6) 9063 (49.7) 18,848 (45.5) 3770 (45.5)
Income quintile, n (%)
Missing 77 (0.4) 17 (0.4) 260 (0.3) 86 (0.5) 175 (0.4) 43 (0.5)
1 4482 (21.2) 970 (22.9) 16,329 (21.0) 4292 (23.5) 8477 (20.5) 1779 (21.5)
2 4656 (22.1) 927 (21.9) 16,832 (21.6) 4084 (22.4) 8602 (20.8) 1822 (22.0)
3 4059 (19.2) 875 (20.7) 15,191 (19.5) 3543 (19.4) 8095 (19.6) 1657 (20.0)
4 4077 (19.3) 744 (17.6) 14,924 (19.2) 3192 (17.5) 8087 (19.5) 1502 (18.1)
5 3755 (17.8) 702 (16.6) 14,380 (18.5) 3034 (16.6) 7971 (19.3) 1480 (17.9)
Years using ACEi or ARB, median
(IQR)
2.17 (1.9-2.3) 1.48 (0.8-2.1)* 2.17 (1.9-2.3) 1.49 (0.7-2.1)* 2.17 (1.9-2.3) 1.72 (0.82-2.2)*
Residence in LTC, n (%) 1618 (7.7) 549 (13.0)* 5701 (7.3) 2232 (12.2)* 2977 (7.2) 579 (7.0)
Number of distinct drugs used in
previous year
12 (9-17) 15 (11-20)* 11 (8-16) 14 (10-19)* 10 (7-14) 11 (7-15)*
Previous hospitalization for respective
outcome,y n (%)
342 (1.6) 208 (4.9)* 9 (0.0) 1576 (8.6)* 710 (1.7) 520 (6.3)*
Chronic kidney disease,y n (%) 12,772 (60.5) 2568 (60.6) 41,316 (53.0) 10,560 (57.9)* 10,057 (24.3) 2012 (24.3)
Diabetes diagnosis, n (%) 13,300 (63.0) 2672 (63.1) 41,932 (53.8) 10,195 (55.9) 19,203 (46.4) 3842 (46.4)
Congestive heart failure,y n (%) 8250 (39.1) 1663 (39.3) 19,050 (24.5) 6437 (35.3)* 6008 (14.5) 1203 (14.5)
Other medication use in preceding 60 days, n (%):
b-Adrenergic blocking agent,z n (%) 8041 (38.1) 1848 (43.6)* 26,852 (34.5) 7403 (40.6)* 12,792 (30.9) 3180 (38.4)*
Potassium supplements, n (%) 279 (1.3) 117 (2.8)* 860 (1.1) 360 (2.0) 387 (0.9) 87 (1.1)
Potassium-sparing diuretics, n (%) 1458 (6.9) 900 (21.2)* 4240 (5.4) 1952 (10.7)* 1866 (4.5) 348 (4.2)
Other diuretics, n (%) 10,450 (49.5) 2353 (55.6)* 34,772 (44.6) 10,682 (58.6)* 16,958 (41.0) 3442 (41.6)
Trimethoprim, n (%) 358 (1.7) 349 (8.2)* 1211 (1.6) 1039 (5.7)* 478 (1.2) 152 (1.8)
NSAIDs, n (%) 1444 (6.8) 423 (10.0)* 5767 (7.4) 1802 (9.9) 3286 (7.9) 747 (9.0)
Digoxin, n (%) 1649 (7.8) 494 (11.7)* 4995 (6.4) 1533 (8.4) 2167 (5.2) 595 (7.2)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; LTC, long-term care; IQR, interquartile range; NSAIDs, nonsteroidal
anti-inﬂammatory drugs.
* Standard difference >0.10.
y Past 3 years prior to index date assessed by database codes.
z b-Blocker.
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Volume 29 2013whom these outcomes developed during the course of
hospitalization. The date of hospitalization served as the index
date for all analyses. Only the ﬁrst instance was considered for
patients with more than 1 such admission during the study
period. Patients were excluded if they had a history of end-
stage renal disease, including patients with kidney trans-
plants in the previous 5 years or any dialysis code in 120 days
preceding the hospitalization date.
From the cohort of patients receiving an ACEi or an ARB,
we selected up to 5 controls for each case, using incidence
density sampling.22 Controls were matched to their corre-
sponding case on age at the index date (within 3 years), sex,
and any history in the past 3 years of chronic kidney disease,
diabetes, or congestive heart failure. Chronic kidney disease
was deﬁned by physician claims, hospitalization records, and
receipt of inpatient or outpatient dialysis.16 We excluded cases
who could not be matched to at least 1 control.
We compared the baseline demographic and clinical
characteristics of cases and controls using standardized
differences; values less than 0.1 indicate good balance for
a given covariate.23 We conducted 3 prespeciﬁed analyses
examining the risk of hyperkalemia, AKI, and stroke associ-
ated with aliskiren use in the 60 days preceding the index date,
with no aliskiren exposure as the reference group. In all
groups, we replicated our analyses using amlodipineprescriptions as a neutral comparator, since amlodipine is
commonly used to treat hypertension and is not classically
associated with hyperkalemia, AKI, or stroke.
For each analysis, conditional logistic regression was used
to estimate the odds ratio (OR) and 95% conﬁdence interval
(CI) for the association between the end point and aliskiren
use. Multivariable conditional logistic regression was used to
adjust for concomitant medical conditions and other drugs
that might modify the risk of these end points.24 All analyses
were performed with SAS version 9.2 (SAS Institute, Cary,
NC). This project was approved by the Research Ethics Board
of the Sunnybrook Health Sciences Centre.Results
During the 28-month study period, we identiﬁed 903,346
patients newly treated with an ACEi or ARB. Within this
cohort, we performed 3 separate case-control studies. We
identiﬁed 4235 case subjects admitted to hospital with
hyperkalemia, 8283 admitted with stroke, and 18,231
admitted with AKI. The characteristics of cases and controls
are shown in Table 1. As a result of the matching process,
cases and controls were similar with respect to age, income
quintile, and history of chronic kidney disease, diabetes mel-
litus, and congestive heart failure in all analyses.
Table 2. Aliskiren use and hospitalization for hyperkalemia, stroke, or acute kidney injury
Exposure (n, %)
Unadjusted OR (95% CI) Adjusted OR (95% CI)Case Control
Hyperkalemia
Aliskiren 30 (0.7) 120 (0.6) 1.3 (0.87-1.94) 1.14 (0.74-1.74)
Amlodipine 904 (21.4) 3956 (18.7) 1.18 (1.09-1.28) 1.09 (1.00-1.19)
Stroke
Aliskiren 47 (0.6) 182 (0.4) 1.3 (0.94-1.79) 1.18 (0.85-1.63)
Amlodipine 1392 (16.8) 6837 (16.5) 1.02 (0.96-1.09) 0.94 (0.88-1.00)
Acute kidney injury
Aliskiren 115 (0.6) 431 (0.6) 1.21 (0.98-1.49) 1.08 (0.87-1.34)
Amlodipine 3669 (20.1) 14001 (18.0) 1.12 (1.08-1.17) 0.99 (0.94-1.03)
CI, conﬁdence interval; OR, odds ratio.
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Risks Associated With Aliskiren UseIn the primary analysis, aliskiren was not associated with
a signiﬁcant increase in the risk of hospitalization for any of
the outcomes of interest (Table 2). After multivariable
adjustment, patients hospitalized with hyperkalemia (adjusted
OR, 1.14; 95% CI, 0.74-1.74), AKI (adjusted OR, 1.08;
95% CI, 0.87-1.34), or stroke (adjusted OR, 1.18; 95% CI,
0.85-1.63) were found to be no more likely than controls to
have received a prescription for aliskiren in the preceding
60 days. We found consistent results in analyses stratiﬁed by
diabetes, chronic kidney disease, and heart failure (Table 3).
In our tracer analyses, amlodipine use was weakly associ-
ated with hyperkalemia (adjusted OR, 1.09; 95% CI,
1.00-1.19). Amlodipine use was also weakly associated with
a reduced risk of hospitalization for stroke (adjusted OR, 0.94;
95% CI, 0.88-1.00) but not for AKI (adjusted OR, 0.99;
95% CI, 0.94-1.03).Discussion
In 3 population-based studies of more than 1.5 million
community-dwelling patients aged 66 years and older, we
found, among patients receiving an ACEi or ARB, no asso-
ciation between hospitalization for severe hyperkalemia, AKI,
or stroke and a recent aliskiren prescription. These results
were unchanged in stratiﬁed analyses of patients with diabetes
mellitus, chronic kidney disease, and congestive heart failure.
Our ﬁndings suggest that despite a biologically plausible
association between aliskiren and these end points, the risk of
hospitalization with severe hyperkalemia, AKI, or stroke is low
when the drug is used together with an ACEi or ARB in
routine practice.Table 3. Analyses stratiﬁed by previous history of diabetes, kidney disease,
Exposure Case, n (%) Control, n (%)
Diabetes
Hyperkalemia 22 (0.8) 91 (0.7)
Acute kidney injury 92 (0.9) 300 (0.7)
Stroke 26 (0.7) 119 (0.6)
Chronic kidney disease
Hyperkalemia 22 (0.9) 84 (0.7)
Acute kidney injury 77 (0.7) 294 (0.7)
Stroke 18 (0.9) 73 (0.7)
Heart failure
Hyperkalemia 9 (0.5) 38 (0.5)
Acute kidney injury 28 (0.4) 69 (0.4)
Stroke * 23 (0.4)
CI, conﬁdence interval; OR, odds ratio.
* Cell sizes lower than 6 suppressed in accordance with institutional privacy polIt is important to note that while these ﬁndings offer some
reassurance regarding aliskiren’s safety, the lack of an associ-
ation between the drug and these outcomes may reﬂect
limitations of our study design. Speciﬁcally, we focused on
patients hospitalized for the outcomes of interest, and we had
no direct measure of potassium or creatinine levels. Patients
admitted with minor increases in potassium or creatinine may
not have been identiﬁed in our databases. As noted, a recent
meta-analysis suggested that aliskiren was associated with an
increased risk of moderate hyperkalemia, but no signiﬁcant
difference in the risk of severe hyperkalemia.12
The recently published Cardiorenal End Points in a Trial
of Aliskiren for Type 2 Diabetes, or ALTITUDE, trial was
terminated prematurely because of lack of efﬁcacy and an
increase in adverse events, speciﬁcally hyperkalemia and renal
impairment. We speculate that the divergent ﬁndings of
ALTITUDE and our study are explained by several observa-
tions. First, by design, the ALTITUDE study included
patients at higher risk (all of them had type 2 diabetes mel-
litus) than was the general population we studied. Second, as
an observational study, we cannot account for unmeasured
differences between patients who received aliskiren and those
who did not. Finally, our study does not include patients with
minor cases of hyperkalemia or renal impairment who are not
hospitalized and are managed in an outpatient setting.
Furthermore, a reduction in levels of angiotensin II has
been postulated as a potential mechanism of renal impairment
and hyperkalemia with the use of ACEi’s and ARBs. This
reduction leads to dilation of the efferent arteriole and reduced
glomerular perfusion pressure (and potentially acute renal
failure), particularly in patients with severe bilateral renalor stroke
Unadjusted OR (95% CI) Adjusted OR (95% CI)
1.26 (0.79-2.01) 1.17 (0.71-1.92)
1.39 (1.09-1.76) 1.29 (1.01-1.65)
1.09 (0.71-1.68) 1.04 (0.68-1.6)
1.38 (0.86-2.22) 1.43 (0.87-2.33)
1.14 (0.89-1.47) 1.09 (0.83-1.42)
1.24 (0.74-2.09) 1.22 (0.72-2.07)
1.24 (0.6-2.56) 1.46 (0.69-3.07)
1.16 (0.74-1.82) 1.19 (0.72-1.97)
0.66 (0.2-2.2) 0.72 (0.21-2.42)
icy.
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Volume 29 2013artery stenosis. This mechanism has been described as “kick-
ing the back door out of the glomerulus.”25 Patients with
heart failure may be at risk of renovascular impairment and as
such, patients in the ALTITUDE trial would be at higher risk
for this complication.
Some limitations of our work also merit emphasis. We used
administrative data and therefore had no knowledge of medi-
cation adherence or use of nonprescription medications that
may have inﬂuenced the risk of hyperkalemia, AKI, or stroke.
However, these limitations apply equally to patients receiving
aliskiren or amlodipine. We could not identify instances of
hyperkalemia or AKI that were mild and treated in the
outpatient setting, or severe cases leading to death in the
prehospital setting. In addition, our ﬁndings derive from an
older patient population, and the generalizability to younger
patients is unknown. However, younger patients will generally
have fewer risk factors for these end points. Finally, discharge
coding for AKI and stroke have been validated.26-28 Although
the accuracy of hospital discharge coding for hyperkalemia has
not been validated, the same limitation applies to our previous
research regarding drug interactions resulting in hyper-
kalemia.10,17,29 It should also be noted that perhaps Ontario
physicians prescribe low doses of an ACEi or ARB and then
add a low dose of aliskiren, limiting the adverse events. This
possibility cannot be recognized by the methods used.
It is important to note that because aliskiren is a relatively
new drug that has not yet enjoyed widespread clinical use, our
study had limited power to detect a major increase in the
outcomes of interest. Indeed, post hoc power calculations for
aliskiren exposure indicate that our study had a 41% power to
detect a 1.36-fold risk of hyperkalemia, a 50% power to detect
a 1.19-fold increased risk of AKI, and a 59% power to detect
a 1.35-fold increase in the risk of stroke, relative effect sizes
suggested by an interim analysis of the ALTITUDE study.13
This is a key interpretive caution.
Despite the above limitations, observational studies such as
this have theoretical advantages over randomized control trials
because they include patients in routine clinical practice,
rather than in the setting of a clinical trial. In general,
community-dwelling patients are likely to be less closely
monitored and at higher risk of adverse drug events than are
those in clinical trials.
It is also interesting to note that in our hyperkalemia
group, patients taking aliskiren were more likely to be on
potassium-retaining medications such as potassium-sparing
diuretics, potassium supplements, and trimethoprim.
Despite this factor, there was still no signiﬁcant increase in the
risk of hospitalization for severe hyperkalemia. This lack of
association may further attest to the drug’s safety, or it may
reﬂect the selective use of the drug in patients who are at lower
risk for other reasons.
Interestingly, we observed a weak but marginally signiﬁ-
cant association between amlodipine use and hospitalization
for hyperkalemia, unexpected in light of the drug’s established
neutral effects on potassium. This association most likely
reﬂects either a spurious ﬁnding or amlodipine’s use in
patients with other risk factors for hyperkalemia, coupled with
the drug’s popularity and the resulting increase in statistical
precision. While a causal association seems unlikely, 1 case
report describes mild hyperkalemia in a patient taking beni-
pidine, a related dihydropyridine.30 Additionally, in vivopotassium-induced aldosterone secretion is reduced by
calcium channel blockade.31 Whether or not the observed
amlodipine association represents cause and effect, the ﬁnding
does not vitiate our primary observations regarding aliskiren.
In conclusion, we found that the use of aliskiren with an
ACEi or an ARB was not associated with an increased risk of
hospitalization with severe hyperkalemia, AKI, or stroke
among Ontarians aged 66 years and older. While this ﬁnding
offers a measure of reassurance regarding the drug’s safety in
routine practice, our study may not have been adequately
powered to detect clinically important increases in the risk of
these adverse events.
The beneﬁts of dual RAAS blockade continue to be the
subject of much research. There is increasing evidence that
such an approach may be harmful. A recent meta-analysis of
dual blockade with ACEi’s and ARBs failed to show beneﬁt in
reducing mortality.32 In addition, the Ongoing Telmisartan
Alone and in Combination With Ramipril Global Endpoint
Trial (ONTARGET) study (Telmisartan, Ramipril or both in
high-risk patients) failed to show any beneﬁt with dual
blockade and also showed an increase in adverse events.1
Based on the results of the CHARM study, which showed
that dual blockade improved left ventricular function and
reduced hospital admissions,33 2 ongoing trials of aliskiren
plus another renineangiotensin system blocker in patients
with heart failure are ongoing.34,35
At present, there does not appear to be a clear indication
for aliskiren’s use in combination with another RAAS block-
ing agent. Although our data suggest that in the general
population, there does not appear to be an increased risk of
these adverse events, there is mounting evidence that combi-
nation therapy imparts few beneﬁts. If a clinician elects to
prescribe aliskiren in combination with another RAAS
blocking agent, close monitoring and follow-up should be
arranged, and other medications that may increase the risk of
adverse effects, such as potassium-sparing diuretics or
nonsteroidal anti-inﬂammatory drugs, should be avoided.Acknowledgements
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